Roche shut down two Huntington’s disease studies tied to Ionis, ending the Phase 2 GENERATION HD2 antisense program after tominersen missed a key efficacy objective. Roche also stopped a separate trial of RG6496 following new data from a parallel animal study. The discontinuations come after additional recent setbacks for Ionis assets in transthyretin amyloidosis cardiomyopathy, underscoring how quickly clinical risk has piled up for the antisense platform in multiple therapeutic areas. Roche and Ionis said decisions were data-driven and based on the totality of evidence, with the companies continuing collaboration on other programs.